Hideaki Mizutani

机构：Saitama Cancer Center

发表论文 51 篇 · 总被引 1420 次 · h-index 15

代表论文

• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study (2024 · Journal of Clinical Oncology · 被引 214)
• First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations (2022 · Journal of Thoracic Oncology · 被引 102)
• Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial (2024 · European Journal of Cancer · 被引 83)
• Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial (2024 · Journal for ImmunoTherapy of Cancer · 被引 63)
• Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer (2023 · JAMA Oncology · 被引 53)
• Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA (2025 · ESMO Open · 被引 32)